Drugs / Amatuximab
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01413451 | Jul 2011 → Nov 2013 | mesothelioma, non-small cell lung carcinoma, ovarian neoplasm, pancreatic ductal adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT01521325 | Sep 2011 → Mar 2013 | malignant pancreatic neoplasm, mesothelioma, non-small cell lung carcinoma, ovarian cancer | Morphotek | Completed | No outcome recorded |
| Phase 1 | NCT01018784 | Nov 2009 → May 2012 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00325494 | May 2006 → Sep 2008 | malignant pancreatic neoplasm, mesothelioma, non-small cell lung carcinoma, ovarian cancer | Morphotek | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02357147 | Nov 2015 → Nov 2018 | malignant mesothelioma | Morphotek | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00738582 | Dec 2008 → Jun 2011 | malignant pleural mesothelioma | Morphotek | Completed | No outcome recorded |
| Phase 2 | NCT00570713 | Dec 2007 → Dec 2009 | malignant pancreatic neoplasm | Morphotek | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
All press releases naming this drug 1 release
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amatuximab | “MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.” NCT00738582 ↗ |
| Known as | MORab-009 | “Amatuximab (MORab-009)” NCT01413451 ↗ |
| Action | Deplete | “amatuximab helps the immune system to kill cells that have high levels of mesothelin.” NCT01413451 ↗ |
| Action | Inhibit | “Mesothelin inhibitor” CHEMBL1742984 ↗ |
| Modality | Monoclonal antibody | “MORAb-009 is a monoclonal antibody that is directed to an antigen on the surface of these cancers.” NCT00325494 ↗ |
| Route | Intravenous | “intravenous injection” NCT00570713 ↗ |
| Target | MSLN | “Mesothelin inhibitor” CHEMBL1742984 ↗ |